AtaiBeckley

New Capabilities

Developer of BPL-003 nasal spray

A single dose of mebufotenin benzoate nasal spray reduced depression scores for at least eight weeks in a 193-patient phase 2b trial published in the Journal of the American Medical Association. The psychedelic compound, found in Sonoran Desert toad venom, cut scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) by 11.1 points at day 29 with a 12-milligram dose, versus 5.8 points for a 0.3-milligram comparator.

Updated Oct 28

Money Moves

As of July 2026: Target of the acquisition

Eli Lilly agreed to buy AtaiBeckley for $6.75 a share in cash, about $2.8 billion, with up to $1 billion more if two drugs hit development targets. The purchase pulls one of the world's largest drugmakers into psychedelic medicine.

Updated Jul 16